COVID-19 UPDATE

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

RSS Feeds

RSS Feeds

RSS (Really Simple Syndication) feeds provide an easy way to keep up with news and information about our company. Most web browsers have built-in RSS readers, or you can use our feeds in an RSS reader or aggregator.

Latest News Releases

Latest SEC Filings

Recent Events

Investor Presentation

More information is coming soon.


Recent BDSI News

BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance January 20, 2022

Total 2021 Net Revenue expected in the range of $165 - $167 million , as compared to previous guidance of $162-$167 million BELBUCA 2021 Net Sales expected to be in the range of $147 - $148 million , as compared to previous guidance of $144-$148 million 2021 EBITDA expected to be in the $40 - $45 ...

Read more
BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032 December 20, 2021

RALEIGH, N.C. , Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that the U.S. ...

Read more
BioDelivery Sciences Reports Solid Third Quarter 2021 Results November 3, 2021

Total Net Revenue of $41.1 Million , an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07 , EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential ...

Read more

Upcoming Events

More events are coming soon.

Stay Connected

Stay up to date on the latest news

Get started now
November 3, 2021 /
Data provided by West LLC. Minimum 15 minutes delayed.